Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.030 UNCHANGED
Streaming Delayed Price Updated: 3:54 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,520
Open 1.020
Bid (Size) 0.9900 (4)
Ask (Size) 1.070 (1)
Prev. Close 1.030
Today's Range 0.9993 - 1.040
52wk Range 0.9512 - 2.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
From Clearmind Medicine Inc.
Via GlobeNewswire

Performance

YTD
-29.0%
-29.0%
1 Month
-11.2%
-11.2%
3 Month
-30.9%
-30.9%
6 Month
-16.3%
-16.3%
1 Year
-10.4%
-10.4%

More News

Read More
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
From Clearmind Medicine Inc.
Via GlobeNewswire
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
SciSparc Shares Are Soaring Monday: What's Going On?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Is Penny Stock Clearmind Gaining Today?
Via Benzinga
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?
Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
What exchange does Clearmind Medicine Inc. - Common Shares trade on?
Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
What is the current price of Clearmind Medicine Inc. - Common Shares?
The current price of Clearmind Medicine Inc. - Common Shares is 1.030
When was Clearmind Medicine Inc. - Common Shares last traded?
The last trade of Clearmind Medicine Inc. - Common Shares was at 04/04/25 03:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.